The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & ... The American Journal of Managed Care: Esketamine Nasal Spray Shows Rapid, Durable Effectiveness in Treatment-Resistant Depression New real-world evidence on esketamine (Spravato; Janssen Pharmaceutical) nasal spray is reinforcing its role as an effective and durable treatment option for adults with treatment-resistant depression ... Yahoo Finance: New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a randomized, double-blind trial found.
Among 379 participants in the efficacy ... Nasdaq: SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Budapest, Hungary — A single dose of intravenous esketamine during delivery or caesarean section appears to reduce the risk for postpartum depression (PPD) by more than 50% in the first 6 weeks, a new ...
esketamine for depression, Esketamine is associated with a 7-point reduction in symptoms of treatment-resistant depression at week 1, with nearly 50% of patients responding by week 4, in new research. Healio: J&J seeks FDA approval of esketamine as monotherapy for treatment-resistant depression Less-common depression treatments, including transcranial magnetic stimulation, ketamine, and esketamine, can boost the effectiveness of antidepressant medications.
